Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (June 2018)
21 slides from Noxopharm's investor presentation, Jun 7, 2018
Slide 1: Noxopharm Corporate Presentation for Public Briefing
Date: 7 June 2018 Sydney, Australia For personal use only ASX Limited ASX: NOX 20 Bridge Street Noxopharm Limited SYDNEY NSW 2000 ABN 50 608 966 123 Registered Office and NOXOPHARM CORPORATE Operational Office: Suite 3, Level 4 PRESENTATION FOR PUBLIC BRIEFING 828 Pacific Highway Gordon NSW 2072 Aus
Slide 2: Forward Looking Statements
Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “shoul
Slide 3: A clinical-stage oncology drug company - Open Briefing June 2018
For personal use only A clinical-stage oncology drug company developing a disruptive technology for the Open Briefing June 2018 treatment of solid cancers by radiotherapy and chemotherapy 1
Slide 4: Unique dual-acting anti-cancer drug
For personal use only Unique dual-acting anti-cancer drug NOX66 Idronoxil (lipophilic form) inhibits DNA repair inhibits PARP-1, topoisomerases 1 and 2 promotes anti-tumour immunity Increases NK (natural killer) cell activity 2
Slide 5: 3-horse race
For personal use only 3-horse race DARRT • Risk mitigation • Identify optimal route to market • Expand post-registration markets CEP DARRT LuPIN 3
Slide 6: CEP: Chemotherapy Enhancement Program
CEP For personal use only Chemotherapy Enhancement Program Objective: v To enable salvage chemotherapy in patients with late-stage, resistant cancers v NOX66 in combination with low-dose cytotoxic chemotherapy v Aim to deliver a meaningful anti-cancer effect in at least 50% patients in a well 4 tole
Slide 7: CEP-1 Phase Sighting study
CEP For personal use only CEP-1 Phase 1 Sighting study Details: v 19 patients; late-stage, metastatic cancer; no remaining standard Rx options v Breast, lung, ovarian, prostate v 14-day NOX66 run-in v 6 cycles; each cycle = NOX66 (7 days) + carboplatin (1 day) each month v 3 patients withdrew volunt
Slide 8: CEP-1 Outcomes
CEP CEP-1 For personal use only Outcomes Safety: • 5 Grade 3 toxicities, all resolved. All other toxicities mild. • No toxicity associated with NOX66 Efficacy: Partial response Stable disease Disease progression Total 3 cycles 0 12 2 14 6 cycles 1 5 4 10* 6 * 12 started: 1 withdrew: 1 sudden death
Slide 9: CEP-2
CEP CEP-2 For personal use only v Phase 2 v NOX66 Dosage: 800 mg v Platinum based therapy. Which drug? • Carboplatin • Cisplatin • Oxaliplatin v Which cancer type(s)? What end-points? v Protocol design • Q3 Meet with Advisory Board • Q4 Final protocol • Early-2019 Study opens 7
Slide 10: DARRT Direct and Abscopal Response to Radio-Therapy
DARRT Direct and Abscopal Response For personal use only to Radio-Therapy Ø Patients with multiple (>3) tumours Ø Irradiate 1-2 tumours (5 days) External Beam RT Ø NOX66 14 days or Stereotactic Body RT Ø Scan + 6 weeks and 12 weeks 8
Slide 11: DARRT: Direct Response
DARRT Direct and Abscopal Response For personal use only to Radio-Therapy Direct Response NOX66 Radiotherapy applied to large Shrinkage of irradiated Seeking complete remission of Direct radio-sensitising effect Direct radio-sensitising irradiated tumours effect tumours for pain relief tumours 9
Slide 12: DARRT: Abscopal Response
DARRT Direct and Abscopal Response For personal use only to Radio-Therapy Abscopal Response NOX66 Low-dose radiotherapy Seeking Direct complete remission radio-sensitising effectof Abscopal response irradiated tumours 10
Slide 13: DARRT-1
DARRT DARRT-1 For personal use only Details: v Phase 1b multi-national study v 24 patients; metastatic castrate-resistant prostate cancer v NOX66 + External beam RT v RT (5-10 days) NOX66 (duration of RT + 7 days) v 4 Cohorts: § 400 mg NOX66 (4 patients) completed § 800 mg NOX66 (4 patients) complet
Slide 14: DARRT-1 Schedule and Data Release
DARRT DARRT-1 For personal use only SCHEDULE v Late-July 2018. Complete treatment and 6-week scans on first 3 cohorts. • Independent review of data • Select NOX66 dosage v Late-Aug 2018. Commence recruitment of Cohort 4. • Target complete recruitment of all 24 patients in Q3 2018 • 12 week review fo
Slide 15: DARRT Other Studies
DARRT Other Studies For personal use only v DARRT-2: Solid tumours • Phase 1b; expanding DARRT-1 research beyond prostate cancer • Provide guidance on criteria which may suggest better response to NOX66 • Decision point – DARRT-1: 12 patient, 6 weeks scan à drive protocol development • Commence stud
Slide 16: LuPIN Lutetium-PSMA In Combination With NOX66
LuPIN Lutetium-PSMA In Combination For personal use only With NOX66 THERANOSTICS 68-Gallium 177-Lutetium 14
Slide 17: LuPIN Lutetium-PSMA In Combination With NOX66
LuPIN Lutetium-PSMA In Combination For personal use only With NOX66 Ø Phase 1b study; investigator-initiated; St Vincent’s Hospital Sydney Ø Late-stage prostate cancer (metastatic castrate- resistant disease) Ø 177 Lutetium-PSMA-617 Brachytherapy THERANOSTICS Ø 6 x monthly intravenous injections of
Slide 18: LuPIN: Next Steps
LUPIN Lutetium-PSMA In Combination For personal use only With NOX66 v LuPIN-1 • Recruitment ongoing – presentation of trial outline at ASCO 2018 • First 4 patients in 5th cycle of therapy; first key data expected late-2018 v Next Steps • Development of expanded LuPIN study • Phase 2 multi-centre, sp
Slide 19: Key metrics
Key metrics ……….. For personal use only 24 Number of Shares 121.9M : Free float 66.8% $1.80 $1.60 Market Cap (6.6.2018) $90M $1.40 $1.20 $1.00 $0.80 $0.60 IPO price 20 cents $0.40 $0.20 $0.00 12 month high/low $1.58/0.29 31/5/17 31/7/17 30/9/17 30/11/17 31/1/18 31/3/18 Average daily turnover $0.54M
Slide 20: Disclaimer
For personal use only Disclaimer • This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 21: Contact
For personal use only Contact 19